Role of p21waf1/cip1 in effects of oxaliplatin in colorectal cancer cells
暂无分享,去创建一个
M. Monden | C. Ngan | I. Takemasa | M. Ikeda | M. Sekimoto | N. Matsuura | Hirofumi Yamamoto | H. Hemmi | T. Matsuzaki | M. Koi | A. Takagi | K. Kitani | Y. Seki | B. Damdinsuren | T. Hata | M. Yasui | Y. Fujie | Xundi Xu | Akimitsu Takagi | Yosuke Seki
[1] Andrew J. Wilson,et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells , 2004, British Journal of Cancer.
[2] Tak W. Mak,et al. Pathways of apoptotic and non-apoptotic death in tumour cells , 2004, Nature Reviews Cancer.
[3] T. Pawlik,et al. Role of cell cycle in mediating sensitivity to radiotherapy. , 2004, International journal of radiation oncology, biology, physics.
[4] D. Altieri. Molecular circuits of apoptosis regulation and cell division control: The survivin paradigm , 2004, Journal of Cellular Biochemistry.
[5] F. Ciardiello,et al. Determination of Molecular Marker Expression Can Predict Clinical Outcome in Colon Carcinomas , 2004, Clinical Cancer Research.
[6] R. L. Hayward,et al. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect. , 2004, Molecular cancer therapeutics.
[7] M. Kasuga,et al. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. , 2003, Carcinogenesis.
[8] 中治 美有紀. IFN-alpha prevents the growth of preneoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat , 2004 .
[9] W. Scheithauer,et al. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Monden,et al. JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosis1. , 2003, Gastroenterology.
[11] F. Zunino,et al. Mechanisms controlling sensitivity to platinum complexes: role of p53 and DNA mismatch repair. , 2003, Current cancer drug targets.
[12] A. Gartel,et al. A new method for determining the status of p53 in tumor cell lines of different origin. , 2003, Oncology research.
[13] B. Chauffert,et al. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins , 2002, Cancer Chemotherapy and Pharmacology.
[14] E. Raymond,et al. Cellular and molecular pharmacology of oxaliplatin. , 2002, Molecular cancer therapeutics.
[15] M. Monden,et al. Differential expression of cyclooxygenase‐2 (COX‐2) in human bile duct epithelial cells and bile duct neoplasm , 2001, Hepatology.
[16] J P Pignon,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. , 2001, The New England journal of medicine.
[17] E. Raymond,et al. Oxaliplatin-induced damage of cellular DNA. , 2000, Molecular pharmacology.
[18] L. Saltz,et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. , 2000, The New England journal of medicine.
[19] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] W. Göhde,et al. Flow cytometric analysis of reverse transcription-PCR products: quantification of p21(WAF1/CIP1) and proliferating cell nuclear antigen mRNA. , 2000, Clinical chemistry.
[21] D. Kerr,et al. Adjuvant Therapy of Colorectal Cancer , 2000, Hospital practice.
[22] S. Leung,et al. Inhibition of proteasome function induced apoptosis in gastric cancer. , 2000, International journal of cancer.
[23] R. James,et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial , 2000, The Lancet.
[24] B. Clurman,et al. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. , 2000, Molecular cell.
[25] M. Bekradda,et al. Oxaliplatin: a new therapeutic option in colorectal cancer. , 1999, Seminars in oncology.
[26] Eric D. Scheeff,et al. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. , 1999, Molecular pharmacology.
[27] I. Schieren,et al. Comparative effects of overexpression of p27Kip1 and p21Cip1/Waf1 on growth and differentiation in human colon carcinoma cells , 1999, Oncogene.
[28] E. Reed. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. , 1998, Cancer treatment reviews.
[29] T. Kunkel,et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.
[30] P. Cruz,et al. IFNγ induction of p21WAF1 in prostate cancer cells: Role in cell cycle, alteration of phenotype and invasive potential , 1998, International journal of cancer.
[31] J. Zlatanova,et al. Proteins that specifically recognize cisplatin‐damaged DNA: a clue to anticancer activity of cisplatin , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[32] Michael Weller,et al. Predicting response to cancer chemotherapy: the role of p53 , 1998, Cell and Tissue Research.
[33] K. Kinzler,et al. A simplified system for generating recombinant adenoviruses. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[34] R. Farouk,et al. Adjuvant therapy for colorectal cancer. , 1997, Current problems in surgery.
[35] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] A. N. Meyer,et al. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[37] K. Paull,et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.
[38] S. Aebi,et al. The role of DNA mismatch repair in platinum drug resistance. , 1996, Cancer research.
[39] J. Eshleman,et al. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[40] G. Colucci,et al. Subcutaneous low-dose interleukin-2 and intravenous 5-fluorouracil plus high-dose levofolinic acid as salvage treatment for metastatic colorectal carcinoma , 1996, Anti-cancer drugs.
[41] M. J. van den Bent,et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer. , 1996, British Journal of Cancer.
[42] J. Morin,et al. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells. , 1996, Drugs under experimental and clinical research.
[43] Xiao-Fan Wang,et al. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[44] Sajeev P. Cherian,et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. , 1994, Cancer research.
[45] Pengcheng Zhou,et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. , 1993, Oncogene.
[46] B. Kramer,et al. A phase II study of continuous infusion 5‐fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma , 1993, Cancer.
[47] M. Christian. The current status of new platinum analogs. , 1992, Seminars in oncology.
[48] V. Brabec,et al. Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexes. , 1992, Nucleic acids research.
[49] G. Blijham. Chemotherapy of colorectal cancer. , 1991, Anti-cancer drugs.
[50] T. Tashiro,et al. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[51] J. Misset,et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[52] M. Buyse,et al. Adjuvant therapy of colorectal cancer. Why we still don't know. , 1988, JAMA.
[53] Barnett Rosenberg,et al. Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .
[54] B. Rosenberg. Fundamental studies with cisplatin. , 1985, Cancer.